XML 188 R134.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaborative and Other Relationships - Alkermes (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Oct. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018
Collaborative arrangements and non-collaborative arrangement transactions |  |  |  |
Research and development |  | $ 3,990.9 | $ 2,280.6 | $ 2,597.2
Potential future milestone payments commitment to third party approximately |  | 10,200.0 |  |
Alkermes |  |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |  |
Research and development |  | $ 32.4 | 53.5 | $ 68.7
Potential future milestone payments commitment to third party approximately |  |  | $ 155.0 |
VUMERITY | Alkermes |  |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |  |
Percentage of royalties as per collaboration | 15.00% | 15.00% |  |
Royalties payable period, post FDA approval |  | 5 years |  |

X
- Definition Percentage of royalties as per collaboration. + References No definition available. + Details
Name: | biib_PercentageOfRoyaltiesAsPerCollaboration
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential future milestone payments commitment to third party approximately. + References No definition available. + Details
Name: | biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Royalties Payable Period, Post FDA Approval + References No definition available. + Details
Name: | biib_RoyaltiesPayablePeriodPostFDAApproval
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_AlkermesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_VUMERITYMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |